ImmunityBio shared a post on X:
“We reported another quarter of strong results, driven by increased demand for ANKTIVA and continued progress across our immunotherapy pipeline. In Q3 2025, we achieved significant year-to-date unit growth of 467% and $75 million in total product sales, reflecting growing adoption in BCG-unresponsive non-muscle invasive bladder cancer.
As we close out the year, we remain committed to expanding access to our therapies, advancing ongoing trials across multiple indications, and executing our long-term vision to transform how cancer is treated. Read the full release, including important cautionary statements about forward-looking information.”
You Can Also Read: “That’s the HOW!” – Dr. Pat Soon-Shiong Explains Bioshield’s Cancer-Fighting Power
